Pre-, peri- and postoperative data were assessed and echocardiographic as well as clinical follow-up was performed. Fifty-seven patients Observed in-hospital mortality was 2.
No paravalvular leakage was seen. Nine patients died during follow-up. This valve can be implanted in all sizes with an incidence of severe PPM below 0.
Introduction During aortic valve replacement AVR , and particularly when a stented bioprosthesis is used, one of the most important goals is to implant a valve size corresponding to the patient's need.
Prosthesis—patient mismatch PPM refers to the presence of a relatively small valve according to the body size, which generates higher transvalvular gradients . PPM is commonly expressed by the size of the effective orifice area EOA divided by the body surface area.
Heparin induced thrombocytopenia was not investigated as a possible cause of thrombocytopenia, as it appears after the 5th postoperative day[ 18 ]. These patients had also higher rate of blood and platelets transfusion.
A prospective randomised trial is needed to confirm our findings. No financial support. Eur J Cardiothorac Surg. Perceval S aortic valve implantation in mini-invasive surgery: the simple sutureless solution. Interact Cardiovasc Thorac Surg.
Thrombocytopenia associated with Perceval sutureless aortic valve replacement in elderly patients: a word of caution. Heart Surg Forum. Thrombocytopenia after aortic valve replacement with Perceval S sutureless bioprosthesis. J Heart Valve Dis. Differences in the recovery of platelet counts after biological aortic valve replacement.
Evaluation of platelet count after isolated biological aortic valve replacement with Freedom Solo bioprosthesis. Thrombocytopenia after aortic valve replacement with freedom solo bioprosthesis: a propensity study.
Ann Thorac Surg. Thrombocytopenia after aortic valve replacement with Freedom Solo stentless bioprosthesis. Yet no publication, until now, has verified its short- and intermediate-term safety and efficacy. Herein, we report our 5-year outcomes with the use of the Magna valve in 70 patients implanted between through at a single center the Cleveland Clinic —including short-term in vivo echocardiographic data, which can be used as a reference for outcomes analyses and for future valve modifications.
Methods Study population For our study, we queried the Cardiovascular Information Registry Cleveland Clinic , a prospective database approved for use in research by the Institutional Review Board. Included in our study population were patients who underwent mitral valve replacement with the Magna valve from through our 4-year study period Fig.
Excluded were patients who underwent mitral valve repairs or replacements with other types of valves. Original Carpentier-Edwards Perimount design. Magna valve based on the original design but now with a lower profile and Therma fix processing Full size image In general the Cleveland Clinic prefers mitral valve repair whenever possible. When replacement is needed, we have primarily used either the St. Jude Medical Biocor or the Carpentier-Edwards Perimount mitral valve bioprosthesis; however, since , our experience with the Magna valve has been gradually accumulating.
Clinical data included demographic variables, comorbidities, operative details, postoperative outcomes, and intermediate-term follow-up results. To confirm preoperative atrial fibrillation, we reviewed the preoperative electrocardiogram. Endpoints Endpoints were postoperative hemodynamic measurements, in-hospital morbidity and mortality, valve-related events, resource utilization, clinically significant structural valve degeneration and intermediate-term survival rates.
To define in-hospital morbidity perioperative myocardial infarction, respiratory failure, sepsis, renal failure, and neurologic complications , we used the Society of Thoracic Surgeons national Adult Cardiac Surgery database. For surviving patients, we used hospital length of stay as a surrogate marker for resource utilization. This cohort study reports the very long-term outcomes of AVR using Carpentier-Edwards Perimount pericardial bioprosthesis in this age group.
Multiple valve replacements were excluded fro m our cohortTwo patients 2. Platelet activation after aortic prosthetic valve surgery. Perceval S aortic valve implantation in mini-invasive surgery: the simple sutureless solution. Thrombocytopenia after aortic valve replacement with Perceval S sutureless bioprosthesis. Magna valve based on the original design but now with a lower profile and Therma fix processing Full size image In general the Cleveland Clinic prefers mitral valve repair whenever possible. These valves are carefully washed after detoxification with a homocysteic acid-free solution and then stored in jars filled with a homocysteic acid-free storage solution. For surviving patients, we used hospital length of stay aortic valve replacement. Original Carpentier-Edwards Perimount design. Differences in the recovery of platelet counts after biological coronary intervention[ 11 ]. Frequencies F and different stroke volumes S were simulated as a surrogate marker for resource utilization.
Mitral annular calcification was the most common operative finding, followed by degenerative disease. However, sutureless valves are well known for their superior hemodynamic performance and this hypothesis is quite unlikely. In the s, Dwight Harken coined the "Ten Commandments" for the perfect prosthetic heart valve. Advanced Search Abstract Prosthesis—patient mismatch PPM remains a controversial issue with the most recent stented biological valves. The median survival rate was 4.
Two patients 2. Eur J Cardiothorac Surg.
Among the most popular are the St. One hundred and sixty-eight The profusion of models in each of these categories in contemporary use is largely the result of failure to produce any single prosthesis with an optimal risk profile, despite seven decades of effort.